Admedus has achieved its first sales of CardioCel in the Middle East and North African (MENA) region. The initial sales of CardioCel have come through an early access program in Qatar. Admedus anticipates additional sales in other MENA countries in the near future.
“This first use of CardioCel in Qatar is particularly important, as the MENA region is one of the fastest growing healthcare areas worldwide and this bodes well for future sales,” says Admedus chief executive officer, Lee Rodne.
Admedus entered into a partnership in 2015 with Genpharm, a specialty marketing and sales healthcare company, to be its exclusive partner for CardioCel in the MENA region. Leveraging Admedus’ existing regulatory approvals outside the region, it is expected that the two companies will work together to produce a number of MENA country product marketing approvals in 2016.
“Cardiovascular and congenital diseases are significant health issues in Qatar and in the MENA region, so this is an important initial use of CardioCel by surgeons there and will have long-reaching positive results for local patients,” says Lee Rodne.
CardioCel is on market in Europe, the US, Canada, Malaysia, Hong Kong and Singapore, and used in over 135 centres globally.
